DBV Technologies to Attend Upcoming Investor Conferences

MONTROUGE, France, Sept. 1, 2016 (GLOBE NEWSWIRE) -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that members of its management team will present and host investor meetings at the following investor events in September, 2016:

• Charles Ruban, Chief Commercial Officer, and Susanna Mesa, Senior Vice President, Strategy, will host investor meetings during Citi's 11th Annual Biotech Conference in Boston, MA on Thursday, September 8, 2016.
• Pierre-Henri Benhamou, Chairman & Chief Executive Officer, David Schilansky, Chief Operating Officer and Susanna Mesa, Senior Vice President, Strategy, will present at the Morgan Stanley Global Healthcare Conference in New York, NY on Monday, September 12, 2016, at 2:15 pm ET.
• Susanna Mesa, Senior Vice President, Strategy, will present at the Rodman & Renshaw 18th Annual Global Investment Conference in New York, NY on Tuesday, September 13, 2016, at 11:40 am ET.
• Pierre-Henri Benhamou, Chairman & Chief Executive Officer and David Schilansky, Chief Operating Officer will present at the Bank of America Merrill Lynch Global Healthcare Conference 2016 in London, UK on Friday, September 16, 2016, at 1:45 pm BST.

A live webcast of the Morgan Stanley Conference will be available on the Investor Relations section of the Company's website: http://www.dbv-technologies.com/en/investor-relations. A replay of the presentation will also be available on DBV's website within 48 hours after the event.

About DBV Technologies 

DBV Technologies developed Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV isalso pursuing a human proof concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.

DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

PDF Version http://hugin.info/156437/R/2038534/759741.pdf

You May Also Be Interested In

• BofA Securities Downgrades W.R. Berkley (WRB) to Underperform
• BofA Securities Upgrades Cintas (CTAS) to Buy
• Dimensional Fund Advisors Ltd. : Form 8.3 - GAMMA COMMUNICATIONS PLC - Ordinary Shares